The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
The drug will be available in 600 hospitals and 105 DTPs
It is developing the drug candidate to potentially treat immunological diseases
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
In clinical trials, treatment proved more effective than other therapies evaluated
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
Subscribe To Our Newsletter & Stay Updated
